Over the past 12 months, 6 insiders at Dianthus Therapeutics, Inc. /DE/ filed 28 open-market SEC Form 4 transactions on DNTH: 0 purchases worth $0 and 28 sales worth $36.2M. Insiders have been net sellers over this period. The most recent filing was on Jul 9, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 9, 26 | Ryan SavitzEVP, CFO & CBO | SELL | 15.3K | $101.97 | $1.6M |
| Jun 17, 26 | Adam M VenessSVP, General Counsel and Sec. | SELL | 16.8K | $81.38 | $1.3M |
| Jun 1, 26 | Simrat RandhawaEVP, Head of R&D | SELL | 16.9K | $91.37 | $1.5M |
| May 8, 26 | Paula Soteropoulos | SELL | 599 | $85.47 | $51K |
| Apr 9, 26 | Ryan SavitzEVP, CFO & CBO | SELL | 8.2K | $89.84 | $739K |
| Mar 24, 26 | Paula SoteropoulosDirector | SELL | 27.6K | $78.05 | $2.2M |
| Mar 12, 26 | Edward CarrCHIEF ACCOUNTING OFFICER | SELL | 23.5K | $85.53 | $1.9M |
| Mar 12, 26 | Marino GarciaCEO AND PRESIDENT | SELL | 65.5K | $85.53 | $5.4M |
| Mar 12, 26 | Simrat RandhawaEVP, Head of R&D | SELL | 33.8K | $81.48 | $2.8M |
| Dec 4, 25 | Ryan SavitzCFO & CBO | SELL | 20.0K | $45.18 | $904K |
| Nov 14, 25 | Simrat RandhawaEVP, Head of R&D | SELL | 109.0K | $38.14 | $4.2M |
| Nov 13, 25 | Simrat RandhawaEVP, Head of R&D | SELL | 42.8K | $37.72 | $1.6M |
| Sep 9, 25 | Ryan SavitzCFO & CBO | SELL | 20.0K | $35.00 | $700K |
| Sep 29, 23 | Peter Evan HarwinDirector,TenPercentOwner | BUY | 24.7K | $13.63 | $336K |
| Sep 26, 23 | Tomas KiselakDirector,TenPercentOwner | BUY | 30.0K | $13.15 | $395K |
| Sep 22, 23 | Simrat RandhawaChief Medical Officer | BUY | 2.0K | $13.20 | $26K |
| Sep 21, 23 | Simrat RandhawaChief Medical Officer | BUY | 2.0K | $13.20 | $26K |
| Sep 19, 23 | Tomas KiselakDirector,TenPercentOwner | BUY | 30.0K | $13.20 | $396K |
| Sep 13, 23 | Tomas KiselakDirector,TenPercentOwner | BUY | 9.4K | $11.76 | $110K |
| Sep 12, 23 | Tomas KiselakDirector,TenPercentOwner | BUY | 14.9K | $10.85 | $162K |
Over the past 12 months, insiders at Dianthus Therapeutics, Inc. /DE/ filed 0 open-market purchases worth $0 and 28 sales worth $36.2M on DNTH, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 9, 26.
The largest recent open-market DNTH insider purchase in our data was $396K by Tomas Kiselak, Director,TenPercentOwner, filed on Sep 19, 23.
6 different insiders at Dianthus Therapeutics, Inc. /DE/ filed open-market SEC Form 4 transactions on DNTH over the last 12 months.
InsiderTape plots every DNTH insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Dianthus Therapeutics, Inc. /DE/ insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →